….And from a patient and market perspective, that 20% in the real world, that cannot tolerate initial chemo radiation, could, instead of being removed from a trial, placed immediately on DCVax-l.
That alone is 20% of the market and, more importantly, 20% of patients that have no where else to turn too, given real hope.
Market Data 
Markets 
AI
